Vitamin D thread -Please use this for your Vit D info.

R.B. · 10-02-2011, 03:22 PM

Serum 25-hydroxyvitamin D is inversely associated with body mass index in cancer
Pankaj G Vashi,1 Carolyn A Lammersfeld,1 Donald P Braun,1 and Digant Guptacorresponding author1
1Cancer Treatment Centers of America® (CTCA) at Midwestern Regional Medical Center, 2520 Elisha Avenue, Zion, IL, 60099, USA

http://www.ncbi.nlm.nih.gov/pmc/arti...4/?tool=pubmed

(Full Free Text)

"Conclusions
Obese cancer patients (BMI >= 30 kg/m2) had significantly lower levels of serum 25(OH)D as compared to non-obese patients (BMI <30 kg/m2). BMI should be taken into account when assessing a patient's vitamin D status and more aggressive vitamin D supplementation should be considered in obese cancer patients.

Background
Serum 25-hydroxyvitamin D [25(OH)D] is the major circulating form of vitamin D and a standard indicator of vitamin D status [1,2]. Several studies have described an inverse relationship between serum 25(OH)D and cancer risk [3-5]. The relationship between regular vitamin D intake and reduced cancer incidence has also been reported [6]. Furthermore, higher plasma 25(OH)D levels are associated with improved survival in prostate [7], breast [8], lung [9], colorectal [10] and ovarian [11] cancers. A better vitamin D status at the time of diagnosis and treatment, adjusted for season of diagnosis, has been shown to improve survival [12,13].
Several factors are involved in the regulation of 25(OH)D including: age; gender [14]; race [15]; dietary intake [2]; season [16]; and sunlight exposure [17]. Recently, the relationship between obesity and vitamin D status has been investigated suggesting decreased bioavailability of 25(OH)D from cutaneous and dietary sources in association with obesity [18]. "

R.B. · 10-02-2011, 03:25 PM

Ann Surg Oncol. 2011 Jul;18(7):1830-6. Epub 2010 Dec 14.
Vitamin D deficiency is correlated with poor outcomes in patients with luminal-type breast cancer.
Kim HJ, Lee YM, Ko BS, Lee JW, Yu JH, Son BH, Gong GY, Kim SB, Ahn SH.
Source

Department of Surgery, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, Korea.

(Full Free Text)

http://www.ncbi.nlm.nih.gov/pmc/arti...7/?tool=pubmed

Abstract
PURPOSE:

Vitamin D deficiency may be an indicator of poor prognosis in patients with breast cancer before surgery. We investigated the association between serum vitamin D concentration and breast cancer prognosis according to intrinsic cancer subtypes.
METHODS:

From June to December 2006, serum 25-OHD was measured in 310 Korean women with breast cancer who were treated at the Asan Medical Center, Korea. Clinicopathologic data were examined to determine the prognostic effects of serum 25-OHD. Expression of estrogen receptor (ER), progesterone receptor (PR), and epidermal growth factor receptor 2 (Her2) were measured using tissue microarrays. Patients were classified with luminal A, luminal B, Her2-enriched, or basal-like subtypes of breast cancer.
RESULTS:

Mean patient age was 48.7 years, and mean serum 25-OHD concentration was 31.4 ± 16.1 ng/ml. The 25-OHD levels were deficient (< 20 ng/ml) in 75 patients (24.2%), insufficient (20-29 ng/ml) in 95 (30.6%), and sufficient (30-150 ng/ml) in 140 (45.2%). Women with deficient 25-OHD levels were at increased risk of recurrence compared with those with sufficient vitamin D levels (P = 0.002). The 25-OHD concentration was inversely associated with prognosis of patients with cancer of the luminal A (P = 0.012) and luminal B subtypes (P =0.023), but not with the prognosis of patients with Her2/neu-enriched (P = 0.245) or triple-negative (P = 0.879) cancer subtypes. This association remained valid after adjustment for age, tumor size, nodal status, and estrogen receptor status (hazards ratio = 3.97; 95% confidence interval = 1.77-9.61).
CONCLUSIONS:

Vitamin D deficiency may be associated with poor outcomes in patients with luminal-type breast cancer.